.jpg "Aerie Pharma (NASDAQ: AERI)")
Cowen & Co. analyst Ken Cacciatore reiterated a Buy rating on Aerie Pharma (NASDAQ: AERI) yesterday and set a price target of $105. The company’s shares closed yesterday at $64.35.
According to TipRanks.com, Cacciatore is a 3-star analyst with an average return of 5.4% and a 49.1% success rate. Cacciatore covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Horizon Pharma Inc, and Mylan Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aerie Pharma with a $86.33 average price target, implying a 34.2% upside from current levels. In a report issued on August 8, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $86 price target.
.
See today’s analyst top recommended stocks >>
Based on Aerie Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $55.02 million. In comparison, last year the company had a GAAP net loss of $28.43 million.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan.
